Open Access
Med Sci (Paris)
Volume 39, Number 5, Mai 2023
Page(s) 445 - 451
Section M/S Revues
Published online 23 May 2023
  1. Ferlay J, Colombet M, Soerjomataram I, et al. Cancer statistics for the year 2020 : An overview. Int J Cancer 2021; Apr 5. doi : 10.1002/ijc.33588. [PubMed] [Google Scholar]
  2. Bagchi S, Yuan R, Engleman EG. Immune Checkpoint Inhibitors for the Treatment of Cancer : Clinical Impact and Mechanisms of Response and Resistance. Annu Rev Pathol Mech Dis 2021; 16 : 223–49. [CrossRef] [PubMed] [Google Scholar]
  3. Xia L, Oyang L, Lin J, et al. The cancer metabolic reprogramming and immune response. Mol Cancer 2021; 20 : 28. [CrossRef] [PubMed] [Google Scholar]
  4. Burke KP, Grebinoski S, Sharpe AH, Vignali DAA. Understanding adverse events of immunotherapy : A mechanistic perspective. J Exp Med 2021; 218 : e20192179. [CrossRef] [PubMed] [Google Scholar]
  5. Toi Y Sugawara S, Sugisaka J, et al. Profiling Preexisting Antibodies in Patients Treated With Anti–PD-1 Therapy for Advanced Non-Small Cell Lung Cancer. JAMA Oncol 2019 ; 5 : 376–383. [CrossRef] [PubMed] [Google Scholar]
  6. Dougan M, Wang Y, Rubio-Tapia A, et al. AGA clinical practice update on diagnosis and management of immune checkpoint inhibitor colitis and hepatitis : Expert Review. Gastroenterology 2021; 160 : 1384–93. [CrossRef] [PubMed] [Google Scholar]
  7. Menzies AM, Johnson DB, Ramanujam S, et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol 2017 ; 28 : 368–376. [CrossRef] [PubMed] [Google Scholar]
  8. Ramos-Casals M, Brahmer JR, Callahan MK, et al. Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers 2020; 6 : 38. [CrossRef] [PubMed] [Google Scholar]
  9. Dow ER, Yung M, Tsui E. Immune Checkpoint Inhibitor-associated Uveitis : Review of Treatments and Outcomes. Ocul Immunol Inflamm 2021; 29 : 203–11. [CrossRef] [PubMed] [Google Scholar]
  10. Johnson DB, Balko JM, Compton ML, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 2016 ; 375 : 1749–1755. [Google Scholar]
  11. Oh DY, Cham J, Zhang L, et al. Immune toxicities elicted by CTLA-4 blockade in cancer patients are associated with early diversification of the T cell repertoire. Cancer Res 2017 ; 77 : 1322–1330. [PubMed] [Google Scholar]
  12. Gopalakrishnan V, Helmink BA, Spencer CN, et al. The influence of the gut microbiome on cancer, immunity, and cancer immunotherapy. Cancer Cell 2018 ; 33 : 570–580. [CrossRef] [PubMed] [Google Scholar]
  13. Laparra A, Champiat S, Michot J-M, et al. [Management of adverse events associated with cancer immunotherapy]. Rev Prat 2021; 71 : 400–7. [PubMed] [Google Scholar]
  14. La Rochefoucauld J de, Noël N, Lambotte O. Management of immune-related adverse events associated with immune checkpoint inhibitors in cancer patients : a patient-centred approach. Intern Emerg Med 2020; 15 : 587–98. [CrossRef] [PubMed] [Google Scholar]
  15. Schneider BJ, Naidoo J, Santomasso BD, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy : ASCO guideline update. J Clin Oncol 2021; 39 : 4073–126. [CrossRef] [PubMed] [Google Scholar]
  16. Malviya N, Tattersall IW, Leventhal J, et al. Cutaneous immune-related adverse events to checkpoint inhibitors. Clin Dermatol 2020; 38 : 660–78. [CrossRef] [PubMed] [Google Scholar]
  17. Tang L, Wang J, Lin N, et al. Immune Checkpoint Inhibitor-associated colitis : From mechanism to management. Front Immunol 2021; 12 : 800879. [CrossRef] [PubMed] [Google Scholar]
  18. Cramer P, Bresalier RS. Gastrointestinal and hepatic complications of immune checkpoint inhibitors. Curr Gastroenterol Rep 2017 ; 19 : 3. [CrossRef] [PubMed] [Google Scholar]
  19. Thompson JA, Schneider BJ, Brahmer J, et al. Management of immunotherapy-related toxicities, Version 1.2019. J Natl Compr Canc Netw 2019 ; 17 : 255–289. [CrossRef] [PubMed] [Google Scholar]
  20. Martin ED, Michot J-M, Rosmorduc O, et al. Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors. JHEP Report 2020; 2. [Google Scholar]
  21. Chuzi S, Tavora F, Cruz M, et al. Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis. Cancer Manag Res 2017 ; 9 : 207–213. [CrossRef] [Google Scholar]
  22. Faje AT, Sullivan R, Lawrence D, et al. Ipilimumab-induced hypophysitis : a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. J Clin Endocrinol Metab 2014 ; 99 : 4078–4085. [CrossRef] [PubMed] [Google Scholar]
  23. Min L, Hodi FS, Giobbie-Hurder A, et al. Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis : a retrospective cohort study. Clin Cancer Res 2015 ; 21 : 749–755. [CrossRef] [PubMed] [Google Scholar]
  24. Cuzzubbo S, Javeri F, Tissier M, et al. Neurological adverse events associated with immune checkpoint inhibitors : Review of the literature. Eur J Cancer 2017 ; 73 : 1–8. [CrossRef] [PubMed] [Google Scholar]
  25. Liu X, Wang Z, Zhao C, et al. Clinical diagnosis and treatment recommendations for ocular toxicities of targeted therapy and immune checkpoint inhibitor therapy. Thorac Cancer 2020; 11 : 810–8. [CrossRef] [PubMed] [Google Scholar]
  26. Kostine M, Finckh A, Bingham CO, et al. EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. Ann Rheum Dis 2021; 80 : 36–48. [CrossRef] [PubMed] [Google Scholar]
  27. Shah M, Tayar JH, Abdel-Wahab N, et al. Myositis as an adverse event of immune checkpoint blockade for cancer therapy. Semin Arthritis Rheum 2019 ; 48 : 736–740. [CrossRef] [PubMed] [Google Scholar]
  28. Delyon J, Mateus C, Lambert T. Hemophilia A induced by ipilimumab. N Engl J Med 2011 ; 365 : 1747–1748. [CrossRef] [PubMed] [Google Scholar]
  29. Perazella MA, Shirali AC. Immune checkpoint inhibitor nephrotoxicity : what do we know and what should we do? Kidney Int 2020; 97 : 62–74. [CrossRef] [PubMed] [Google Scholar]
  30. Jain V, Bahia J, Mohebtash M, et al. Cardiovascular complications associated with novel cancer immunotherapies. Curr Treat Options Cardiovasc Med 2017 ; 19 : 36. [CrossRef] [PubMed] [Google Scholar]
  31. van der Kooij MK, Suijkerbuijk KPM, Aarts MJB, et al. Safety and efficacy of checkpoint inhibition in patients with melanoma and preexisting autoimmune disease : A cohort study. Ann Intern Med 2021; 174 : 641–8. [CrossRef] [PubMed] [Google Scholar]
  32. Sroussi M, Fluckiger A, Zitvogel L. Un bactériophage du microbiote intestinal induit une réponse anti-tumorale par un mécanisme de réactivité croisée. Med Sci (Paris) 2021; 37 : 970–2. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.